Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

S. Gallego, I. Zanetti, D. Orbach, D. Ranchère, J. Shipley, A. Zin, C. Bergeron, GL. de Salvo, J. Chisholm, A. Ferrari, M. Jenney, HC. Mandeville, T. Rogers, JHM. Merks, P. Mudry, H. Glosli, GM. Milano, S. Ferman, G. Bisogno, European Paediatric...

. 2018 ; 124 (15) : 3201-3209. [pub] 20180524

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19035220

BACKGROUND: Alveolar rhabdomyosarcoma (aRMS) with lymph node involvement (N1 classification) accounts for up to 10% of all cases of RMS. The prognosis is poor, and is comparable to that of distant metastatic disease. In the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) RMS2005 protocol, patients with a histologic diagnosis of aRMS/N1 received intensified chemotherapy with systematic locoregional treatment. METHODS: Patients with aRMS/N1 were enrolled prospectively after primary surgery/biopsy and fusion status was assessed in tumor samples. All patients received 9 cycles of induction chemotherapy and 6 months of maintenance therapy. Local treatment included radiotherapy to the primary site and lymph nodes with or without secondary surgical resection. RESULTS: A total of 103 patients were enrolled. The clinical characteristics of the patients were predominantly unfavorable: 90% had macroscopic residual disease after initial surgery/biopsy, 63% had locally invasive tumors, 77% had a tumor measuring >5 cm, and 81% had disease at unfavorable sites. Fusion genes involving forkhead box protein O1 (FOXO1) were detected in 56 of 84 patients. Events occurred in 52 patients: 43 developed disease recurrence, 7 had disease that was refractory to treatment, and 2 patients developed second neoplasms. On univariate analysis, unfavorable disease site, tumor invasiveness, Intergroup Rhabdomyosarcoma Study group III, and fusion-positive status correlated with worse prognosis. The 5-year event-free survival rate of patients with fusion-positive tumors was 43% compared with 74% in patients with fusion-negative tumors (P = .01). On multivariate analysis, fusion positivity and tumor invasiveness proved to be unfavorable prognostic markers. CONCLUSIONS: Fusion status and tumor invasiveness appear to have a strong impact on prognosis in patients with aRMS/N1. Fusion status will be used to stratify these patients in the next EpSSG RMS study, and treatment will be intensified in patients with fusion-positive tumors. Cancer 2018. © 2018 American Cancer Society.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035220
003      
CZ-PrNML
005      
20191014085929.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cncr.31553 $2 doi
035    __
$a (PubMed)29797665
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gallego, Soledad $u Pediatric Oncology and Hematology, Children's Hospital Vall d'Hebron, Barcelona, Spain.
245    10
$a Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) / $c S. Gallego, I. Zanetti, D. Orbach, D. Ranchère, J. Shipley, A. Zin, C. Bergeron, GL. de Salvo, J. Chisholm, A. Ferrari, M. Jenney, HC. Mandeville, T. Rogers, JHM. Merks, P. Mudry, H. Glosli, GM. Milano, S. Ferman, G. Bisogno, European Paediatric Soft Tissue Sarcoma Study Group (EpSSG),
520    9_
$a BACKGROUND: Alveolar rhabdomyosarcoma (aRMS) with lymph node involvement (N1 classification) accounts for up to 10% of all cases of RMS. The prognosis is poor, and is comparable to that of distant metastatic disease. In the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) RMS2005 protocol, patients with a histologic diagnosis of aRMS/N1 received intensified chemotherapy with systematic locoregional treatment. METHODS: Patients with aRMS/N1 were enrolled prospectively after primary surgery/biopsy and fusion status was assessed in tumor samples. All patients received 9 cycles of induction chemotherapy and 6 months of maintenance therapy. Local treatment included radiotherapy to the primary site and lymph nodes with or without secondary surgical resection. RESULTS: A total of 103 patients were enrolled. The clinical characteristics of the patients were predominantly unfavorable: 90% had macroscopic residual disease after initial surgery/biopsy, 63% had locally invasive tumors, 77% had a tumor measuring >5 cm, and 81% had disease at unfavorable sites. Fusion genes involving forkhead box protein O1 (FOXO1) were detected in 56 of 84 patients. Events occurred in 52 patients: 43 developed disease recurrence, 7 had disease that was refractory to treatment, and 2 patients developed second neoplasms. On univariate analysis, unfavorable disease site, tumor invasiveness, Intergroup Rhabdomyosarcoma Study group III, and fusion-positive status correlated with worse prognosis. The 5-year event-free survival rate of patients with fusion-positive tumors was 43% compared with 74% in patients with fusion-negative tumors (P = .01). On multivariate analysis, fusion positivity and tumor invasiveness proved to be unfavorable prognostic markers. CONCLUSIONS: Fusion status and tumor invasiveness appear to have a strong impact on prognosis in patients with aRMS/N1. Fusion status will be used to stratify these patients in the next EpSSG RMS study, and treatment will be intensified in patients with fusion-positive tumors. Cancer 2018. © 2018 American Cancer Society.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a forkhead box protein O1 $x genetika $7 D000071161
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a lymfatické uzliny $x účinky léků $x patologie $x chirurgie $7 D008198
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x epidemiologie $x genetika $x patologie $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a pediatrie $7 D010372
650    12
$a prognóza $7 D011379
650    _2
$a alveolární rhabdomyosarkom $x farmakoterapie $x epidemiologie $x genetika $x patologie $7 D018232
650    _2
$a rizikové faktory $7 D012307
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zanetti, Ilaria $u Padova University Hospital, Padova, Italy.
700    1_
$a Orbach, Daniel $u Pediatric Oncology, SIREDO Oncology Center, Institute Curie, Paris Sciences and Letters University, Paris, France.
700    1_
$a Ranchère, Dominique $u IHOPE/Center Leon Berard, Lyon, France.
700    1_
$a Shipley, Janet $u Institute of Cancer Research, London, United Kingdom.
700    1_
$a Zin, Angelica $u Pediatric Research Institute Citta della Speranza, Padova, Italy.
700    1_
$a Bergeron, Christophe $u IHOPE/Center Leon Berard, Lyon, France.
700    1_
$a de Salvo, Gian Luca $u Clinical Trials and Biostatistics Unit, Veneto Oncologic Institute IOV-IRCCS, Padova, Italy.
700    1_
$a Chisholm, Julia $u The Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom.
700    1_
$a Ferrari, Andrea $u National Tumor Institute, Milan, Italy.
700    1_
$a Jenney, Meriel $u Pediatric Oncology, Children Hospital for Wales Cardiff and Vale University Health Board, Cardiff, United Kingdom.
700    1_
$a Mandeville, Henry C $u The Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom.
700    1_
$a Rogers, Timothy $u University Hospitals Bristol National Health Service Foundation Trust, Bristol, United Kingdom.
700    1_
$a Merks, Johannes H M $u Pediatric Oncology, Emma Children's Hospital-Academic Medical Center, Amsterdam, The Netherlands.
700    1_
$a Mudry, Peter $u Pediatric Oncology, University Children's Hospital Brno, Brno, Czech Republic.
700    1_
$a Glosli, Heidi $u Pediatric Oncology, Oslo University Hospital, Oslo, Norway.
700    1_
$a Milano, Giuseppe Maria $u Pediatric Oncology, Children's Hospital Bambino Gesu, IRCCS, Rome, Italy.
700    1_
$a Ferman, Sima $u Pediatric Oncology, National Cancer Institute, Rio de Janeiro, RJ, Brazil.
700    1_
$a Bisogno, Gianni $u Padova University Hospital, Padova, Italy.
710    2_
$a European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
773    0_
$w MED00001031 $t Cancer $x 1097-0142 $g Roč. 124, č. 15 (2018), s. 3201-3209
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29797665 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014090353 $b ABA008
999    __
$a ok $b bmc $g 1451880 $s 1073770
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 124 $c 15 $d 3201-3209 $e 20180524 $i 1097-0142 $m Cancer $n Cancer $x MED00001031
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options